In depth characterization of the mucosal microbiota in patients with IBD using novel, potent high-throughput approaches and their interaction with the immune system

Completed

Conditions: Crohn's disease
Inflammatory Bowel Disease
Ulcerative Colitis
10017969
10003816

Registration Number: NL-OMON36766

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 88

Inclusion Criteria

*18 year old male or female, able to give informed consent
Established Crohn*s disease or ulcerative colitis (according to the Lennard-Jones criteria), or patients scheduled for diverting ostomy due to IBD.
control patients: patients who undergo intestinal resection due to a gastrointestinal malignancy

Exclusion Criteria

Ischemia of the bowel
Positive stool cultures or parasite tests for common enteric pathogens (with exeption of non pathogenic parasites such as Blastocystis hominis or Endolimax nana)
Use of Antiobiotics in preceding 4 weeks
use of probiotics in preceding 8 weeks

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Nature and transmural spatial distribution of the enteric microbiota in IBD<br /><br>patients.<br /><br>- Changes in mucosal microbiota of the sigmoid in IBD after diverting ostomy.<br /><br>- Phenotype and characterise the immune cells involved in IBD.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Presence of microbial DNA in granuloma*s of CD patients.<br /><br>- Assessment of co-localisation and signalling between invading microbes,<br /><br>lamina propria macrophages dendritic cells and adaptive and innate immune cells.<br /><br>- Alterations of phagosome maturation and autophagy, as well as apoptosis of<br /><br>mucosal macrophages and dendritic cells in IBD.</p><br>